STING upregulation strategies to potentiate STING immunotherapy

References

• 1. Sato S, Sawada Y, Nakamura M. STING signaling and skin cancers. Cancers (Basel) 13(22), 5603 (2021).
  Medline CASGoogle Scholar
• 2. Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J. Clin. Med. 9(10), 3323 (2020).
  MedlineGoogle Scholar
• 3. Dane EL, Belessiotis-Richards A, Backlund C et al. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat. Mater. 21, 710–720 (2022).
  Medline CASGoogle Scholar
• 4. Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLOS One 8(10), e77846 (2013).
  Medline CASGoogle Scholar
• 5. Xia T, Konno H, Barber GN. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76(22), 6747–6759 (2016).
  Medline CASGoogle Scholar
• 6. Li L, Yin Q, Kuss P et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10(12), 1043–1048 (2014).
  Medline CASGoogle Scholar
• 7. Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING agonists as cancer therapeutics. Cancers (Basel) 13(11), 2695 (2021).
  Medline CASGoogle Scholar
• 8. Zhong B, Zhang L, Lei C et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity 30(3), 397–407 (2009).
  Medline CASGoogle Scholar
• 9. Xing J, Zhang A, Zhang H et al. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat. Commun. 8(1), 945 (2017).
  MedlineGoogle Scholar
• 10. Gentili M, Liu B, Papanastasiou M et al. ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signalling. Nat. Commun. 14(1), 611 (2023).
  Medline CASGoogle Scholar
• 11. Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 155(3), 688–698 (2013).
  Medline CASGoogle Scholar
• 12. Chu TT, Tu X, Yang K, Wu J, Repa JJ, Yan N. Tonic prime-boost of STING signalling mediates Niemann–Pick disease type C. Nature 596(7873), 570–575 (2021).
  Medline CASGoogle Scholar
• 13. Kang J, Wu J, Liu Q, Wu X, Zhao Y, Ren J. Post-translational modifications of STING: a potential therapeutic target. Front. Immunol. 13, 888147 (2022).
  Medline CASGoogle Scholar
• 14. Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science (1979) 350(6260), 568–571 (2015).
  CASGoogle Scholar
• 15. Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18(1), 152 (2019).
  MedlineGoogle Scholar
• 16. Della Corte CM, Sen T, Gay CM et al. STING pathway expression identifies NSCLC with an immune-responsive phenotype. J. Thorac. Oncol. 15(5), 777–791 (2020).
  MedlineGoogle Scholar
• 17. Li X, Li Y, Zhao Z et al. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition. Cancer Med. 12(4), 4864–4881 (2023).
  Medline CASGoogle Scholar
• 18. Chon HJ, Kim H, Noh JH et al. STING signaling is a potential immunotherapeutic target in colorectal cancer. J. Cancer 10(20), 4932–4938 (2019).
  Medline CASGoogle Scholar
• 19. De Queiroz NMGP, Xia T, Konno H, Barber GN. Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis. Mol. Cancer Res. 17(4), 974–986 (2019).
  MedlineGoogle Scholar
• 20. Cho W, Won S, Choi Y et al. Targeted protein upregulation of STING for boosting the efficacy of immunotherapy. Angew. Chem. Int. Ed. Engl. 62(18), e202300978 (2023).
  Medline CASGoogle Scholar
• 21. Li Q, Lin L, Tong Y et al. TRIM29 negatively controls antiviral immune response through targeting STING for degradation. Cell Discov. 4(1), 13 (2018).
  MedlineGoogle Scholar
• 22. Falahat R, Berglund A, Perez-Villarroel P et al. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat. Commun. 14(1), 1573 (2023).
  Medline CASGoogle Scholar
• 23. Lai J, Fu Y, Tian S et al. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice. Mol. Ther. 29(5), 1758–1771 (2021).
  Medline CASGoogle Scholar